Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer.
Suitable for use in ELISA, Western Blot, Immunohistochemistry, and Neutralization. Other applications have not been tested.
Optimal dilutions to be determined by the researcher.
RPMI 1640 with 10% fetal calf serum
NCI-Ag 4/1 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|Partially purified human PAI-1|
|Purified by Protein A affinity chromatography. |
|Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide.|
|Recognizes human PAI-1. Binds to an epitope consisting of amino acids 110-145. No cross-reactivity is observed with PAI-2 as tested by ELISA, Westen Blot and Neutralization of inhibitory activity. No reactivity is observed with any other human plasma protein when tested by Western Blot.|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
1. Andreasen PA (2007) Current Drug Target 9:1030-1041 2. Loskutoff DJ, et al (1999) Regulation of adhesion by PAI-1. APMIS 107:54-61. 3.Andreasen PA, Kjøller L, Christensen (1997) A review. Int J Cancer 2:1-22. 4. Harbeck N, Kates RE, Look MP (2002) Cancer Res 62:4617-22.5. Grøndahl-Hansen J, et al (1993) Cancer Res 53:2513-2521 6. Nielsen LS, Aet al (1986) Thrombos Haemostas 55:206 212. 7. Lund LR, et al (1988) Mol Cell Endocrinol 60:43 53. 8. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) J Imm Meth 203:55-65.|